Hookipa Pharma Inc/HOOK

$0.80

3.88%
-
1D1W1MYTD1YMAX

About Hookipa Pharma Inc

HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Company’s replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its oncology portfolio includes three disclosed programs, HB-200, HB-300 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-300 is in development for the treatment of prostate cancer and is in an ongoing Phase II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers.

Ticker

HOOK

Sector

Tervishoid

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Joern Aldag

Employees

156

Headquarters

New york, United States

HOOK Metrics

BasicAdvanced
$64.65M
Market cap
-
P/E ratio
-$0.99
EPS
1.03
Beta
-
Dividend rate

What the Analysts think about HOOK

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 6 analysts.
472.5% upside
High $6.50
Low $3.00
$0.80
Current price
$4.58
Average price target

HOOK Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-279.41% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$6.8M
161.54%
Net income
$-19M
5.56%
Profit margin
-279.41%
-59.64%

HOOK Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 19.05%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.17
-$0.27
-$0.22
-$0.17
-
Expected
-$0.22
-$0.23
-$0.21
-$0.21
-$0.19
Surprise
-20.93%
19.47%
5.35%
-19.05%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Hookipa Pharma Inc stock

Buy or sell Hookipa Pharma Inc stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing